Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

Next Previous
Trial Profile

Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azithromycin (Primary) ; Fluticasone propionate (Primary) ; Montelukast (Primary)
  • Indications Bacterial infections; Bronchiolitis obliterans
  • Focus Therapeutic Use
  • Acronyms FAM for BOS

Most Recent Events

  • 01 Sep 2021 Results of an analysis assessing the biomarkers associated with Bronchiolitis obliterans syndrome diagnosis after lung transplantation are also associated with Bronchiolitis obliterans syndrome diagnosis after allogeneic HCT ( a data from who participated in a phase II multicenter study of FAM treatment (NCT01307462) and control from (NCT00637689 and NCT01902576)) published in the Transplantation and Cellular Therapy
  • 22 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
  • 04 Jun 2013 Planned End Date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top